15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 21 firms covering Kymera Therapeutics Inc, 19 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $90.00 to $155.00, a moderate spread. The average target of $124.75 sits 18% above the current $106.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 20 to 19 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.03 next quarter toward $-4.35 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 ratings
Strong Buy
Strong Buy00%
Buy1990%
Hold210%
Sell00%
Strong Sell00%
Based on 21 analysts giving stock ratings to Kymera Therapeutics Inc.
As of Jul, 19 of 21 firms rate KYMR a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KYMR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.03
Range $-1.56 – $-0.67 · 19 analysts · +9% YoY
Next period, 19 analysts expect Kymera Therapeutics Inc to earn $-1.03 a share (range $-1.56 – $-0.67), versus $-0.94 a year earlier. Full-year consensus is $-3.51, growing to $-4.35 the year after.
REVENUE · NEXT QUARTER
$8.3M
Range $-1.0M – $42.2M · 19 analysts · +199% YoY
Revenue is expected to reach $8.3M (range $-1.0M – $42.2M), +199.0% year-over-year. Full-year consensus is $85.4M, rising to $41.0M next year.
Top analysts covering Kymera Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KYMR.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$155.00+46.1% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$134.00+26.3% to target
Overall win rate
46%
+ Follow
#3
Jeff Jones
Oppenheimer · Rank #197
Buy
$120.00+13.1% to target
Overall win rate
34%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$125.00+17.8% to target
Overall win rate
41%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$125.00+17.8% to target
Overall win rate
29%
+ Follow
KYMR stock forecast FAQ
What is KYMR's average 12-month price target?+
The 20 analysts with a live target average $124.75 for Kymera Therapeutics Inc over the next 12 months, ranging from a $155.00 high to a $90.00 low.
Is KYMR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 21 analyst ratings, 19 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KYMR?+
The Street-high target is $155.00 (B. Riley Securities), and the Street-low is $90.00 (Guggenheim). The average of all 20 active targets is $124.75.
How many Wall Street analysts cover KYMR?+
21 analysts have an active rating on Kymera Therapeutics Inc, and 20 firms carry a live 12-month price target.
Who is the most accurate analyst covering KYMR?+
Among analysts who currently cover KYMR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $155.00 target.
What is Kymera Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.03 per share (range $-1.56 – $-0.67) across 19 analysts. Full-year EPS is projected at $-3.51, rising to $-4.35 the following year.
How much revenue is Kymera Therapeutics Inc expected to report next quarter?+
Consensus revenue is $8.3M (range $-1.0M – $42.2M). Full-year revenue is projected at $85.4M, growing to $41.0M next year.
Have analysts been upgrading or downgrading KYMR lately?+
As of Jul, 19 of 21 firms rate KYMR a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KYMR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
